These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 21061685)

  • 1. [TARCEVA Clinical Registry].
    Skricková J; Pesek M; Zatloukal P; Kolek V; Salajka F; Koubková L; Krejcí J; Tomísková M; Grygárková Y; Havel L; Hrnciarik M; Skalová B; Stícha M
    Klin Onkol; 2010; 23(5):361-3. PubMed ID: 21061685
    [No Abstract]   [Full Text] [Related]  

  • 2. The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer.
    Comis RL
    Oncologist; 2005 Aug; 10(7):467-70. PubMed ID: 16079313
    [No Abstract]   [Full Text] [Related]  

  • 3. [Tyrosine kinase inhibitor erlotinib (Tarceva) improves survival of patients with multiple previous treatments].
    Krankenpfl J; 2004; 42(5-6):158. PubMed ID: 15527222
    [No Abstract]   [Full Text] [Related]  

  • 4. Targeted kinase inhibitors in lung cancer: from EGFR to patients.
    Apolone G; La Vecchia C; Garattini S
    Eur J Cancer; 2006 Jan; 42(2):124-5. PubMed ID: 16324837
    [No Abstract]   [Full Text] [Related]  

  • 5. Erlotinib treatment for persistent spontaneous pneumothorax in non-small cell lung cancer: a case report.
    Ren SX; Zhou SW; Zhang L; Zhou CC
    Chin Med J (Engl); 2010 Dec; 123(23):3501-3. PubMed ID: 22166539
    [No Abstract]   [Full Text] [Related]  

  • 6. Modern treatment of lung cancer: case 2. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma.
    Garfield DH
    J Clin Oncol; 2005 Oct; 23(30):7738-40. PubMed ID: 16234533
    [No Abstract]   [Full Text] [Related]  

  • 7. Erlotinib: optimizing therapy with predictors of response?
    Goodin S
    Clin Cancer Res; 2006 May; 12(10):2961-3. PubMed ID: 16707589
    [No Abstract]   [Full Text] [Related]  

  • 8. Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer.
    Technol Eval Cent Assess Program Exec Summ; 2011 Mar; 25(6):1-5. PubMed ID: 21638942
    [No Abstract]   [Full Text] [Related]  

  • 9. [Maintenance treatment of non-small cell lung cancer].
    Hansen O; Schytte T
    Ugeskr Laeger; 2010 Mar; 172(12):954. PubMed ID: 20334788
    [No Abstract]   [Full Text] [Related]  

  • 10. Economics and the new generation of targeted therapies for non-small cell lung cancer.
    Ramsey SD
    J Natl Cancer Inst; 2010 Mar; 102(5):287-8. PubMed ID: 20160167
    [No Abstract]   [Full Text] [Related]  

  • 11. [New medications; erlotinib].
    Cohen AF; Dubois EA; van Bronswijk H
    Ned Tijdschr Geneeskd; 2006 Dec; 150(49):2703-4. PubMed ID: 17194007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erlotinib and maintenance therapy of non-small cell lung cancer. Inadequate assessment; authorisation unjustified.
    Prescrire Int; 2011 Oct; 20(120):234. PubMed ID: 21970082
    [No Abstract]   [Full Text] [Related]  

  • 13. [New era in cancer therapy. Gefitinib: small molecule--strong action].
    Arnheim K
    MMW Fortschr Med; 2004 Nov; 146(47):70-1. PubMed ID: 15624666
    [No Abstract]   [Full Text] [Related]  

  • 14. EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer.
    Shih JY; Gow CH; Yang PC
    N Engl J Med; 2005 Jul; 353(2):207-8. PubMed ID: 16014893
    [No Abstract]   [Full Text] [Related]  

  • 15. Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer.
    Reddy GK
    Clin Lung Cancer; 2005 Nov; 7(3):163-5. PubMed ID: 16354309
    [No Abstract]   [Full Text] [Related]  

  • 16. Pulmonary fibrosis in a patient treated with erlotinib.
    Bach JP; Kiessling AM; Kleinhans A; Faoro C; Gorg C; Riera-Knorrenschild J; Schwella N; Wagner HJ; Neubauer A
    Onkologie; 2006 Jul; 29(7):342-3. PubMed ID: 16874020
    [No Abstract]   [Full Text] [Related]  

  • 17. Using EGFR status to personalize treatment: lung cancer researchers reach a milestone.
    Friedrich MJ
    J Natl Cancer Inst; 2009 Aug; 101(15):1039-41. PubMed ID: 19638503
    [No Abstract]   [Full Text] [Related]  

  • 18. Follicular rash during therapy with erlotinib (Tarceva).
    Gerdes S; Mrowietz U
    J Dtsch Dermatol Ges; 2006 Oct; 4(10):855-7. PubMed ID: 17010175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The TULUNG clinical registry].
    Spelda S; Skřičková J; Bortlíček Z; Hejduk K; Pešek M; Zatloukal P; Kolek V; Salajka F; Koubková L; Tomíšková M; Grygárková Y; Havel L; Hrnčiarik M; Zemanová M; Sixtová D; Roubec J; Coupková H; Košatová K
    Klin Onkol; 2012; 25(5):383-4. PubMed ID: 23102201
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety profiles of erlotinib therapy in patients with advanced non-small-cell lung cancer.
    Hotta K; Kiura K
    Expert Rev Anticancer Ther; 2011 Jul; 11(7):991-7. PubMed ID: 21806322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.